2American Psychiatric Association.Diagnostic and Statistical Manual of Mental Disorders.4thed.Washington,DC:American Psychiatric Association,1994,135-180. 被引量:1
3Folstein MF,Folstein SE,Mchugh PR.Mini-mental state:a practical method for grading the cognitive state of patients for the clinician.J Psychiatr Res,1975,12 (3):189. 被引量:1
1Petrella JR, Coleman RE, Doraiswamy PM. Neuroimaging and early diagnosis of Alzheimer disease: a look to the future. Radiology, 2003, 227(2): 613. 被引量:1
2Fleminger S, Oliver DL, Lovestone S, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work groups under the auspices of the departm ent of Human and Healh Services Task force on Alzheimer's disease. Neurology, 1998, 51 (S1): 17. 被引量:1
4Wisniewski HW, Wegiel J. The neuropathology of Alzheimer's disease.Neuroimaging Clin North Am, 1995,5(1) . 45. 被引量:1
5Killiany EJ, Hyman BT, Gomez Isla T, et al. MRI measures of entorhinal cortex vs hippocampus in preclinical AD. Neurology, 2002,58 (8):1188. 被引量:1
6Du AT, Schuff N, Zhu XP, et al. Atrophy rates of entorhinal cortex in AD and normal Aging. Neurology, 2003,60(3): 481. 被引量:1
7Xu YO, Brien PC, Kokmen E, et al. Usefulness of MRI measures of entohinal cortex versus hippocampus in AD. Neurology, 2000, 54 (9):1760. 被引量:1
8Dixon RM, Bradley KM, Budge MM, et al. Longitudinal quantitative proton magnetic resonance spectroscopy of the hippocampus in Alzheimer's disease. Brain, 2002,125(10): 2332. 被引量:1
9Schuff N, Capizzano AA, Du AT, et al. Selective reduction of N-acetylaspartate in medial temporal and parietal lobes in AD. Neurology, 2002,58(6): 928. 被引量:1
10Ernst T, Chang L, Melchor R, et al. Frontotemporal dementia and early Alzheimer disease: differentiation with frontal lobe H-1 MR spectroscopy.Radiology, 1997, 203(3): 829. 被引量:1
2Nordberg A, Rinne JO, Kadir A, et al. The use of PET in Alzheimer disease[J]. Nat Rev Neurol, 2010, 6(2): 78-87. 被引量:1
3Mosconi L, Mistur R, Switalski R, et al. FDG2 PET changes in brain glucose metabolism from normal cognition to pathologically verified Alzheimer's disease [J]. Eur J Nucl Med Mol Imaging, 2009, 36(5): 811-822. 被引量:1
4Mosconi L. Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease[J]. Eur J Nucl Med Mol Imaging, 2005, 32: 486-510. 被引量:1
5Li Y, Rinne JO, Mosconi L, et al. Regional analysis of FDG and PIB-PET images in normal aging, mild cognitive impairment, and Alzheimer's disease[J]. Eur J Nucl Med Mol Imaging, 2008, 35: 2169-2181. 被引量:1
6Tolboom N, Yaqub M, Boellaard R, et al. Test-retest variability of quantitative [HC]PIB studies in Alzheimer's disease[J]. Eur J Nucl Med Mol Imaging, 2009, 36: 1629-1638. 被引量:1
7Razifar P, Ringheim A, Engler H, et al. Masked-Volume-Wise PCA and "reference Logan" illustrate similar regional differences in kinetic behavior in human brain PET study [J]. BMC Neurol, 2009, 9(2): 1-8. 被引量:1
8Cairns N J, Ikonomovic MD, Benzinger T, et al. Absence of Pittsburgh Compound B Detection of Cerebral Amyloid Beta in a Patient With Clinical, Cognitive, and Cerebrospinal Fluid Markers of Alzheimer Disease[J]. Arch Neurol, 2009, 66(12): 1557-1562. 被引量:1
9Rabinovici GD, Jagust WJ. Amyloid Imaging in Aging and Dementia: Testing the Amyloid Hypothesis in Vivo [J]. Behav Neurol. 2009.21(1): 117-128. 被引量:1
10Edis OP, Archer HA, Gerhard A, et al. Microglia, amyloid, and cognition in Alzheimer' s disease: An [11C] (R) PK11195-PET and [11C]PIB-PET study[J]. Neur Dis, 2008, 32: 412-419. 被引量:1